HYPERION sotatercept study has positive results, stops early

The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial hypertension reduced the risk of disease progression. The trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here